urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2015-0-3-42-53urovest-18Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESОТДАЛЕННЫЕ РЕЗУЛЬТАТЫ ДИСТАНЦИОННОЙ ЛУЧЕВОЙ ТЕРАПИИ У ПАЦИЕНТОВ С ВПЕРВЫЕ ВЫЯВЛЕННЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ С РАЗЛИЧНЫМ РИСКОМ ПРОГРЕССИРОВАНИЯLONG-TERM RESULTS OF EXTERNAL BEAM RADIATION THERAPY IN MEN WITH NEWLY DIAGNOSED PROSTATE CANCER WITH DIFFERENT RISK OF PROGRESSIONДемешкоП. Д.DemeshkoP. D.pdemeshko@icloud.comКрасныйС. А.KrasnyS. A.sergeykrasny@tut.byГосударственное учреждение «Республиканский научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова»БеларусьN.N. Alexandrov National Cancer Centre of Belarus, Minsk, BelarusBelarus201520092015034253Copyright © Демешко П.Д., Красный С.А., 20152015Демешко П.Д., Красный С.А.Demeshko P.D., Krasny S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/18

Целью настоящей работы явилась оценка раково-специфической выживаемо- сти пациентов с впервые выявленным раком предстательной железы после дистанционной лучевой терапии по радикальной программе. Проанализированы результаты лечения 178 па- циентов, прошедших 3D-конформную лучевую терапию в Государственном учреждении «Республиканский научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова» на линейных ускорителях электронов в период 2005-2008 гг. На основании данных об уровне простат-специфического антигена, степени местного распространения опухоли и суммы баллов Глисона пациенты распределены на четыре группы риска прогрес- сирования. 9-летняя раково-специфическая выживаемость в группах низкого, промежуточ- ного, высокого и крайне высокого риска прогрессирования составила 81,3±0,1%, 94,3±0,04%, 63,4±0,1% и 49,1±0,09% соответственно (р < 0,005). Указанный показатель также стати- стически значимо коррелировал с возрастом: выживаемость в группе моложе 70 лет и 70 лет и старше составила 61,6±0,07% и 70,2±0,09% соответственно (р = 0,02).

The goal of the study was to evaluate cancer-specific survival in men with newly diagnosed prostate cancer after external beam radiotherapy. The long-term results of 178 patients treated with 3D-confirmal radiotherapy at N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus in 2005-2008 were analyzed. According to prostate-specific antigen level, clinical stage and Gleason sum patients were stratified into four groups of progression. 9-years cancerspecific survival in patients with low, intermediate, high and very high risk was 81,3±0,1%, 94,3±0,04%, 63,4±0,1% and 49,1±0,09%, respectively (р < 0,005).

рак предстательной железылучевая терапияраковоспецифическая выживаемостьprostate cancerradiation therapycancer-specific survivalReferencesОкеанов, А.Е. Статистика онкологических заболеваний в Республике Беларусь (2003-2012) / А.Е. Океанов, П.И. Моисеев, Л.Ф. Левин ; Под редакцией О.Г. Суконко. – Минск : РНПЦ ОМР им. Н.Н. Александрова, 2013. – 373 с.Океанов, А.Е. Статистика онкологических заболеваний в Республике Беларусь (2003-2012) / А.Е. Океанов, П.И. Моисеев, Л.Ф. Левин ; Под редакцией О.Г. Суконко. – Минск : РНПЦ ОМР им. Н.Н. Александрова, 2013. – 373 с.Biochemical outcome after radical prostatec- tomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. / A.V.D’Amico R.Whittington, S.B. Malkowicz et al. // JAMA – 1998. – Vol. 280. – P. 969-974.Biochemical outcome after radical prostatec- tomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. / A.V.D’Amico R.Whittington, S.B. Malkowicz et al. // JAMA – 1998. – Vol. 280. – P. 969-974.Prostate cancer, version 2.2014 / J.L. Mohler, P.W. Kantoff, A.J. Armstrong et al. // J. Natl. Compr. Canc. Netw. – 2014. – Vol. 12 (5). – P. 686-718.Prostate cancer, version 2.2014 / J.L. Mohler, P.W. Kantoff, A.J. Armstrong et al. // J. Natl. Compr. Canc. Netw. – 2014. – Vol. 12 (5). – P. 686-718.Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer / G.D. Grossfeld, D.M. Latini, D.P. Lubeck et al. // J Urol. – 2003. – Vol. 169. – P.157–163.Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer / G.D. Grossfeld, D.M. Latini, D.P. Lubeck et al. // J Urol. – 2003. – Vol. 169. – P.157–163.Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy / O. Yossepowitch, S.E. Eggener, A.M. Serio et al. // Eur. Urol. – 2008. – Vol. 53. – P. 950–959.Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy / O. Yossepowitch, S.E. Eggener, A.M. Serio et al. // Eur. Urol. – 2008. – Vol. 53. – P. 950–959.Cooperberg, M.R. Time trends and local variation in primary treatment of localized prostate cancer / M.R. Cooperberg, J.M. Broering, P.R. Carroll // J Clin. Oncol. – 2010. – Vol. 28. – P.1117–1123.Cooperberg, M.R. Time trends and local variation in primary treatment of localized prostate cancer / M.R. Cooperberg, J.M. Broering, P.R. Carroll // J Clin. Oncol. – 2010. – Vol. 28. – P.1117–1123.Multimodal treatment for high-risk prostate cancer with high-dose intensitymodulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial / A. Guttilla, R. Bortolus, G. Giannarini et al. // Radiation Oncology – 2014. – Vol. 9. – P. 24-34.Multimodal treatment for high-risk prostate cancer with high-dose intensitymodulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective phase II trial / A. Guttilla, R. Bortolus, G. Giannarini et al. // Radiation Oncology – 2014. – Vol. 9. – P. 24-34.Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group / P. Grimm, I. Billiet, D. Bostwick et al. // BJU Int. – 2012. – Vol. 109 (Suppl. 1). – P. 22-29.Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group / P. Grimm, I. Billiet, D. Bostwick et al. // BJU Int. – 2012. – Vol. 109 (Suppl. 1). – P. 22-29.Natural history of progression after PSA elevation following radical prostatectomy / C.R. Pound, A.W. Partin, M.A. Eisenberger et al. // J.A.M.A. – 1999. – Vol. 281 (17). – P. 1591–1597.Natural history of progression after PSA elevation following radical prostatectomy / C.R. Pound, A.W. Partin, M.A. Eisenberger et al. // J.A.M.A. – 1999. – Vol. 281 (17). – P. 1591–1597.Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes / P. Sooriakumaran, T. Nyberg, O. Akre et al. // B.M.J. – 2014. – Vol. 26. – P. 348.Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes / P. Sooriakumaran, T. Nyberg, O. Akre et al. // B.M.J. – 2014. – Vol. 26. – P. 348.High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective / Y. Yoshioka, O. Suzuki, Y. Otani et al.// J. Contemp. Brachytherapy. – 2014. – Vol. 6. – P. 91-98.High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective / Y. Yoshioka, O. Suzuki, Y. Otani et al.// J. Contemp. Brachytherapy. – 2014. – Vol. 6. – P. 91-98.Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival / W.D. Heemsbergena, A. Al-Mamganib, A. Slotc et al. // Lebesque Radiotherapy and Oncology. – 2014. – Vol. 110. – P. 104–109.Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival / W.D. Heemsbergena, A. Al-Mamganib, A. Slotc et al. // Lebesque Radiotherapy and Oncology. – 2014. – Vol. 110. – P. 104–109.Escalated dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial / D.P. Dearnaley, G. Jovic, I. Syndikus et al. // Lancet Oncol. – 2014. – Vol. 15. – P. 464–473.Escalated dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial / D.P. Dearnaley, G. Jovic, I. Syndikus et al. // Lancet Oncol. – 2014. – Vol. 15. – P. 464–473.Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes / M.J. Zelefsky, Y. Yamada, Z. Fuks et al. // Int. J. Radiat. Oncol. Biol. Phys. – 2008. – Vol. 71. – P. 1028-1033.Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes / M.J. Zelefsky, Y. Yamada, Z. Fuks et al. // Int. J. Radiat. Oncol. Biol. Phys. – 2008. – Vol. 71. – P. 1028-1033.

The authors declare that there are no conflicts of interest present.